Baird lowered the firm’s price target on Zimmer Biomet (ZBH) to $117 from $125 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results and although frustrated, are sticking with the name.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH: